Screener
Aquestive Therapeutics, Inc. AQST Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liability related to the sale of future revenue, net at beginning of the period | $63,023 | $63,718 |
| Royalties related to the sale of future revenue | (976) | (938) |
| Amortization of issuance costs | 121 | 243 |
| Liability related to the sale of future revenue, net at end of the period (includes current portion of $1,000 and $1,000, respectively) | $62,168 | $63,023 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s royalty — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported royalty — revenue of $976K in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s royalty — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s royalty — revenue increased by 6.8% year-over-year, from $914K to $976K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s royalty — revenue?
- Over 3 years (2021 to 2025), Aquestive Therapeutics, Inc.'s royalty — revenue has grown at a -5.2% compound annual growth rate (CAGR), from -$1.1M to $938K.
- What does royalty — revenue mean?
- This metric represents the total gross income recognized from intellectual property licensing agreements and royalty-bearing product sales within the specific business segment. It reflects the company's ability to monetize its proprietary technology and pharmaceutical formulations through third-party commercialization or partnership arrangements. Monitoring this revenue stream is essential for assessing the long-term value of the company's patent portfolio and the success of its out-licensing strategy.
Ask your AI about Aquestive Therapeutics, Inc.'s royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude